[go: up one dir, main page]

WO1996014865A1 - Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse - Google Patents

Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse Download PDF

Info

Publication number
WO1996014865A1
WO1996014865A1 PCT/US1995/014774 US9514774W WO9614865A1 WO 1996014865 A1 WO1996014865 A1 WO 1996014865A1 US 9514774 W US9514774 W US 9514774W WO 9614865 A1 WO9614865 A1 WO 9614865A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
antibody
agent
donor
Prior art date
Application number
PCT/US1995/014774
Other languages
English (en)
Inventor
John G. Gribben
Lee M. Nadler
Gary S. Gray
Original Assignee
Repligen Corporation
Dana-Farber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corporation, Dana-Farber Cancer Institute filed Critical Repligen Corporation
Priority to AU41583/96A priority Critical patent/AU4158396A/en
Publication of WO1996014865A1 publication Critical patent/WO1996014865A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)

Definitions

  • Allogeneic bone marrow transplantation is an effective treatment for many hematological malignancies and severe aplastic anemia (see e.g., Thomas, E.D. (1983) J. Clin. Oncol. 1:517-531; O'Reilly, R.J. et al. (1983) Blood 62:942-964; and Storb, T. et al. Semin. Hematol. 2:27-34).
  • GVHD graft versus host disease
  • GVHD GVHD
  • a general immunosuppressant such as cyclosporine A or methotrexate
  • Use of such agents is associated with deleterious side effects, including kidney damage and an increased susceptibility to infections.
  • Another approach taken to minimize or eliminate GVHD has been to deplete donor bone marrow of T cells in an attempt to remove alloreactive T cells (see e.g., Martin, P.J. et al. (1987) Adv. Immunol. 40:379).
  • T cell depletion has been found to reduce the occurrence of GVHD, this treatment also reduces the success of bone marrow engraftment. Additionally, depletion of T cells from donor bone marrow used to treat hematological malignancies reduces the anti-leukemic activity (also referred to as the graft versus leukemia response, or GVL) of the donor cells (see e.g., Goldman, J.M. et al. (1988) Ann. Intern. Med. 108:806-814; Marmont, A.M. et al. (1991) Blood 78:2120-2130).
  • GVL graft versus leukemia response
  • the presence of alloreactive T cells within a bone marrow graft has the detrimental effect of inducing GVHD
  • the presence of at least some T cells within the graft is beneficial both for successful engraftment and for anti-leukemic responses.
  • a therapy that effectively inhibits the responses of alloreactive T cells within donor bone marrow while permitting the continued presence and function of other T cells within the graft would therefore be of great advantage in the addressing the problem of GVHD while promoting the efficacy of bone marrow engraftment.
  • TCR antigen-specific T cell receptor
  • costimulatory signal provided by ligation of one or more other T cell surface receptors.
  • TCR antigen-specific T cell receptor
  • a costimulatory signal can be generated in a T cell by stimulation of the T cell through a cell surface receptor CD28 (Harding, F. A. (1992) Nature 356:607-609).
  • CD28 ligands include members of the B7 family of proteins, such as B7-1(CD80) and B7-2 (CD86) (Freedman, A.S. et al. (1987) J. Immunol. 137:3260-3267; Freeman, G.J. et al. (1989) J. Immunol. 143:2714-2722; Freeman, G.J. et al. (1991) J. Exp. Med. 174:625-631 ; Freeman, G.J. et al. (1993) Science 262:909-911 ; Azuma, M. et al.
  • CTLA4 Another surface receptor on T cells related to CD28 termed CTLA4 (Linsley, P.S. (1991) J. Exp. Med. 174:561-569; Freeman, G.J. et al. (1993) Science 262:909-911).
  • CTLA4Ig fusion protein which binds both B7-1 and B7-2, has been used to inhibit rejection of cardiac allografts and pancreatic islet xenografts (see e.g., Turka, L.A. et al. (1992) Proc. Natl. Acad. Sci. USA 89, 11102- 11 105; Lin, H. et al. ( 1993) J. Exp. Med. 178:1801-1806; Lenschow, D.J. et al. (1992) Science 257, 789-792).
  • This invention features improved methods for inhibiting graft versus host disease in a bone marrow transplant recipient while preserving T cell mediated function against both tumor and pathogens in the recipient.
  • This invention is based, at least in part, on the discovery that an inhibitor of a costimulatory signal in T cells can be used in vitro to inhibit inappropriate donor T cell responses to alloantigen and. thus, inhibit graft versus host disease in bone marrow transplantation.
  • the inhibitor of a costimulatory signal in T cells is preferably an agent which inhibits an interaction between a costimulatory receptor on the T cell (e.g., CD28 and/or CTLA4) and a costimulatory molecule (e.g., B7-1 and/or B7-2) on a cell presenting antigen to the T cell.
  • a costimulatory receptor on the T cell e.g., CD28 and/or CTLA4
  • a costimulatory molecule e.g., B7-1 and/or B7-2
  • the inhibitor of a costimulatory signal can be. for example, an antibody (or fragment thereof) which binds the receptor or the costimulatory molecule, a soluble form of the receptor or costimulatory molecule or a peptide fragment or other small molecule designed to inhibit a costimulatory signal in T cells.
  • a preferred inhibitor is a soluble CTLA4-immunoglobulin fusion protein (CTLA4Ig) or an anti-B7-1 antibody or an anti-B7-2 antibody.
  • CTLA4Ig soluble CTLA4-immunoglobulin fusion protein
  • a much preferred inhibitor is a combination of an anti-B7-1 and an anti-B7-2 antibody.
  • a T cell response is inhibited by contacting the T cell in vitro with at least one inhibitor of a costimulatory signal in an antigen specific T cell.
  • an agent such as a combination of anti-B7-1 and anti-B7-2 antibodies or a soluble form of CTLA4 can be used to treat the donor bone marrow in vitro, to thereby inhibit donor T cell responses to cells expressing recipient alloantigens, prior to administration of the bone marrow to the recipient.
  • donor cells can be contacted with the inhibitor of a costimulatory signal in T cells in vitro in the presence of recipient cells and then administered to the recipient without further in vivo treatment of the recipient with the inhibitor.
  • the inhibitor or other immunosuppressive agent e.g., cyclosporine A
  • the inhibitor or other immunosuppressive agent can be administered in vivo to the transplant recipient.
  • Figure 7 is a graphic representation of T cell proliferation in a primary mixed lymphocyte reaction between HLA disparate individuals treated with either CTLA4Ig, control immunoglobulin (Ig), or phosphate buffered saline (PBS) (control).
  • CTLA4Ig control immunoglobulin
  • PBS phosphate buffered saline
  • Figure 2 is a graphic representation of T cell proliferation in a primary mixed lymphocyte reaction between HLA disparate individuals treated with either anti-B7-1 monoclonal antibody, anti-B7-2 monoclonal antibody, both anti-B7-1 and anti-B7-2 monoclonal antibodies, CTLA4Ig, control immunoglobulin (CIg) or control antibody against peripheral blood lymphocytes.
  • Figures 3A and 3B are graphic representations of T cell proliferation in response to either NIH3T3 cells transfected with B7-1 (t/B7-1) or B7-2 (t/B7-2) or allogeneic peripheral blood lymphocytes bone marrow proliferation treated with various doses of CTLA4Ig (below. 1 ⁇ g/ml: Figure 3 A and from 1 to 10 ⁇ g/ml: Figure 3B).
  • Figure 4 is a graphic representation of the results of T cell proliferation assay of a secondary MLR against the original donor cells or third party cells following a primary MLR performed in the presence of media alone, cyclosporin A (CsA), an anti-MHC class II antibody, an anti-ICAM-1 antibody, CTLA4Ig, an anti-B7-1 antibody, an anti-B7-2 antibody, or a combination of an anti-B71 and an anti-B7-2 antibody.
  • CsA cyclosporin A
  • Figure 5 a-d are graphic representations of the results of T cell proliferation assays of a secondary MLR after culturing the cells for 0, 0.5, 1, 1.5, 2, 3, 5, or 6 days in the presence of anti-B7-1 antibody (a), anti-B7-2 antibody (b), CTLA4Ig (c) or anti-B7-1 and anti-B7-2 (d).
  • Figure 6 depicts the frequency of alloreactive precursor helper T lymphocytes (pHLT) in fully MHC matched donor and stimulator cells incubated in a primary MLR in the presence of media alone, or with anti-B7-1 antibody ( ⁇ -B7-1), an anti-B7-2 antibody ( ⁇ -B7-2), anti-B7-1 and anti-B7-2 ( ⁇ B7-1 + ⁇ B7-2), CTLA4Ig, or CIg.
  • Figure 7 depicts the frequency of alloreactive precursor helper T lymphocytes (pHLT) in MHC mismatched donor bone marrow treated with either irradiated allogeneic stimulator cells (host) or third party cells and CTLA4Ig or anti-ICAM.
  • Figure 8 depicts the frequency of alloreactive precursor helper T lymphocytes (pHLT) in MHC mismatched donor bone marrow treated with irradiated allogeneic stimulator cells and CTLA4Ig, control immunoglobulin (Ig) or cyclosporine A (CsA).
  • pHLT alloreactive precursor helper T lymphocytes
  • Figure 9 depicts the frequency of alloreactive precursor helper T lymphocytes (pHLT) in MHC mismatched donor bone marrow treated with irradiated allogeneic stimulator cells and anti-B7-1 antibody ( ⁇ B7-1), anti-B7-2 antibody ( ⁇ B7-2), anti-B7-1 and anti-B7-2 antibodies ( ⁇ -B7-1 + ⁇ -B7-2), CTLA4Ig, or CIg.
  • pHLT alloreactive precursor helper T lymphocytes
  • This invention features methods for inhibiting antigen specific T cell responses in vitro by use of at least one agent which inhibits a costimulatory signal in T cells.
  • the phrase "inhibiting or inhibition of a T cell response” refers to a reduction in or substantial elimination of at least one T cell response, such as T cell proliferation,
  • lymphokine secretion or induction of an effector function e.g., induction of cytotoxic T cell activity or antibody production by B cells
  • an effector function e.g., induction of cytotoxic T cell activity or antibody production by B cells
  • the phrase "inhibiting or inhibition of a T cell response" is intended to encompass suppression of the response of a T cell to an antigen as well as induction of unresponsive in the T cell to the antigen, also referred to herein as induction of anergy in the T cell.
  • a T cell which has been rendered unresponsive, or anergic, to a specific antigen exhibits substantially reduced or eliminated responses (e.g., proliferation and/or lymphokine production) upon reexposure to the antigen.
  • the response of a donor T cell to a specific antigen exhibits substantially reduced or eliminated responses (e.g., proliferation and/or lymphokine production) upon reexposure to the antigen.
  • the response of a donor T cell to a specific antigen exhibits substantially
  • alloantigens is inhibited to reduce or substantially eliminate graft versus host disease in a bone marrow transplant recipient.
  • a T cell is contacted with at least one inhibitor of a costimulatory signal in the T cell.
  • An "inhibitor of a costimulatory signal” or an “agent which inhibits generation of a costimulatory signal” interferes with, blocks or substantially eliminates formation of or delivery of a second signal in the T cell which, together with a first, antigen specific, signal mediated through the TCR/CD3 complex, is necessary to induce an antigen specific response by the T cell.
  • this second or costimulatory signal is mediated by a T cell surface receptor such as CD28 and/or CTLA4 (or related molecule) upon interaction with a ligand such as B7-1 and/or B7-2, (or related molecule, e.g., B7-3) on a cell presenting antigen to the T cell (e.g., on a B cell, on a "professional" antigen-presenting cell, or APC, such as a T cell surface receptor such as CD28 and/or CTLA4 (or related molecule) upon interaction with a ligand such as B7-1 and/or B7-2, (or related molecule, e.g., B7-3) on a cell presenting antigen to the T cell (e.g., on a B cell, on a "professional" antigen-presenting cell, or APC, such as a
  • T cell a T cell surface receptor
  • costimulatory molecules T cell surface receptors to which such costimulatory molecules bind (e.g., CD28, CTLA4) are collectively referred to herein as "costimulatory receptors”.
  • an inhibitor of a costimulatory signal in a T cell is an agent which inhibits an interaction between a receptor on the T cell and a costimulatory molecule on a cell presenting antigen to the T cell.
  • This type of agent also referred to herein as a "costimulatory blocking agent” can be a soluble form of the receptor on the T cell (or a related receptor on the T cell which similar binding specificity), a soluble form of the costimulatory molecule(s), or an antibody (or fragment thereof) which binds to either the receptor or the costimulatory molecule.
  • a preferred costimulatory inhibitor is CTLA4-immunoglobulin fusion protein (CTLA4Ig), a soluble form of the CTLA4 receptor on T cells which binds to both B7-1 and B7-2.
  • CTLA4Ig CTLA4-immunoglobulin fusion protein
  • An even more preferred costimulatory inhibitor is a combination of an anti-B7-1 and an anti-B7-2 antibody.
  • the costimulatory inhibitor acts intracellularly to inhibit generation of or delivery of a costimulatory signal in a T cell by a CD28- and/or CTL A4-associated signal transduction pathway.
  • an agent used to inhibit an antigen specific T cell response can be an antibody (or fragment thereof).
  • Antibodies suitable for use in the methods of the invention are available in the art (e.g., from the American Type Culture Collection. Rockville, MD, or commercially, e.g., from Becton-Dickinson or Immunotech) or can be prepared by standard techniques for making antibodies.
  • the term "antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen. Structurally, the simplest naturally occurring antibody (e.g...
  • IgG comprises four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a naturally-occurring antibody. Thus, these antigen-binding fragments are also intended to be designated by the term "antibody”.
  • binding fragments encompassed within the term antibody include (i) an Fab fragment consisting of the VL, VH, CL and CH1 domains; (ii) an Fd fragment consisting of the VH and CHI domains; (iii) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a dAb fragment (Ward et al., (1989) Nature 241:544-546) which consists of a VH domain; (v) an isolated complimentarity determining region (CDR); and (vi) an F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
  • Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described for whole antibodies.
  • the term "antibody” is further intended to include bispecific and chimeric molecules having an antigen binding portion.
  • a synthetic linker can be made that enables them to be made as a single protein chain (known as single chain Fv (scFv); Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) PNAS 85:5879-5883) by recombinant methods.
  • single chain Fv single chain Fv
  • Such single chain antibodies are also encompassed within the term "antibody”.
  • an animal is immunized with an appropriate immunogen.
  • immunogen is used herein to describe a composition typically containing a protein or peptide as an active ingredient used for the preparation of antibodies against the protein or peptide. It is to be understood that the protein or peptide can be used alone, or linked to a carrier as a conjugate, or as a peptide polymer.
  • the immunogen should contain an effective, immunogenic amount of the peptide or protein (optionally as a conjugate linked to a carrier).
  • the effective amount of the immunogen per unit dose depends on, among other things, the species of animal inoculated, the body weight of the animal and the chosen immunization regimen, as is well known in the art.
  • the immunogen preparation will typically contain peptide concentrations of about 10 micrograms to about 500 milligrams per immunization dose, preferably about 50 micrograms to about 50 milligrams per dose.
  • An immunization preparation can also include an adjuvant as part of the diluent.
  • Adjuvants such as complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA) and alum are materials well known in the art. and are available commercially from several sources.
  • Either soluble or membrane bound protein or peptide fragments are suitable for use as an immunogen.
  • a purified form of protein such as may be isolated from a natural source or expressed recombinantly by conventional techniques known in the art, can be directly used as an immunogen.
  • synthetic peptides can alternatively be employed towards which antibodies can be raised for use in this invention.
  • the purified protein can also be covalently or noncovalently modified with non-proteinaceous materials such as lipids or carbohydrates to enhance immunogenicity or solubility.
  • a purified protein can be coupled with or incorporated into a viral particle, a replicating virus. or other microorganism in order to enhance immunogenicity.
  • immunogens it is also possible to immunize an animal with whole cells which express a protein on their surface against which an antibody is to be raised (e.g., T cells or antigen presenting cells expressing surface molecules of interest can be used as immunogens).
  • nucleic acid e.g., DNA
  • immunogen is also intended to include nucleic acid encoding a protein or peptide against which antibodies are to be raised (see e.g., Tang, D.C. et al. (1992) Nature 356:152-154; Eisenbraun, M.D. et al. (1993) DNA Cell Biol.
  • Polyclonal antibodies are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of an immunogen and an adjuvant.
  • animals are typically immunized against a protein, peptide or derivative by combining about 1 ⁇ g to 1 mg of protein with Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with 1/5 to 1/10 the original amount of immunogen in Freund's complete adjuvant (or other suitable adjuvant) by subcutaneous injection at multiple sites.
  • the animals are bled and the serum is assayed for specific antibody titer (e.g., by ELISA). Animals are boosted until the titer plateaus.
  • aggregating agents such as alum can be used to enhance the immune response.
  • Such mammalian-produced populations of antibody molecules are referred to as "polyclonal" because the population comprises antibodies with differing immunospecificities and affinities for the immunogen.
  • the antibody molecules are then collected from the mammal (e.g., from the blood) and isolated by well known techniques, such as protein A chromatography, to obtain the IgG fraction.
  • the antibodies may be purified by immunoaffinity chromatography using solid phase-affixed immunogen.
  • the antibody is contacted with the solid phase-affixed immunogen for a period of time sufficient for the immunogen to immunoreact with the antibody molecules to form a solid phase-affixed immunocomplex.
  • the bound antibodies are separated from the complex by standard techniques.
  • monoclonal antibody or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.
  • Monoclonal antibodies can be prepared using a technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497; see also Brown et al. (1981) J. Immunol 127:539-46; Brown et al. (1980) J Biol Chem 255:4980-83; Yeh et al.
  • a monoclonal antibody can be produced by the following method, which comprises the steps of: (a) Immunizing an animal with a protein (or peptide thereof). The immunization is typically accomplished by administering the immunogen to an immunologically competent mammal in an immunologically effective amount, i.e., an amount sufficient to produce an immune response.
  • the mammal is a rodent such as a rabbit, rat or mouse. The mammal is then maintained for a time period sufficient for the mammal to generate high affinity antibody molecules.
  • Antibody production is detected by screening the serum from the mammal with a preparation of the immunogen protein. These screening methods are well known to those of skill in the art, e.g., enzyme-linked immunosorbent assay (ELISA) and/or flow cytometry.
  • ELISA enzyme-linked immunosorbent assay
  • a suspension of antibody-producing cells removed from each immunized mammal secreting the desired antibody is then prepared.
  • the animal e.g., mouse
  • somatic antibody-producing lymphocytes are obtained.
  • Antibody-producing cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals. Spleen cells are preferred, and can be mechanically separated into individual cells in a physiologically tolerable medium using methods well known in the art.
  • Mouse lymphocytes give a higher percentage of stable fusions with the mouse myelomas described below. Rat, rabbit and frog somatic cells can also be used.
  • the spleen cell chromosomes encoding desired immunoglobulins are immortalized by fusing the spleen cells with myeloma cells, generally in the presence of a fusing agent such as polyethylene glycol (PEG).
  • a fusing agent such as polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques; for example, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from the American Type Culture Collection
  • the resulting cells which include the desired hybridomas, are then grown in a selective medium, such as HAT medium, in which unfused parental myeloma or lymphocyte cells eventually die. Only the hybridoma cells survive and can be grown under limiting dilution conditions to obtain isolated clones.
  • the supernatants of the hybridomas are screened for the presence of antibody of the desired specificity, e.g., by immunoassay techniques using the antigen that has been used for immunization. Positive clones can then be subcloned under limiting dilution conditions and the monoclonal antibody produced can be isolated.
  • a selective medium such as HAT medium
  • Hybridomas produced according to these methods can be propagated in vitro or in vivo (in ascites fluid) using techniques known in the art.
  • the individual cell line may be propagated in vitro, for example in laboratory culture vessels, and the culture medium containing high concentrations of a single specific monoclonal antibody can be harvested by decantation, filtration or centrifugation.
  • the yield of monoclonal antibody can be enhanced by injecting a sample of the hybridoma into a histocompatible animal of the type used to provide the somatic and myeloma cells for the original fusion. Tumors secreting the specific monoclonal antibody produced by the fused cell hybrid develop in the injected animal.
  • the body fluids of the animal such as ascites fluid or serum, provide monoclonal antibodies in high concentrations.
  • Immunodeficient or nude mice may be used or the hybridoma may be passaged first into irradiated nude mice as a solid subcutaneous tumor, cultured in vitro and then injected intraperitoneally into pristane primed, irradiated nude mice which develop ascites tumors secreting large amounts of specific human monoclonal antibodies.
  • compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like.
  • An exemplary synthetic medium is Dulbecco's minimal essential medium
  • DMEM Dulbecco et al. (1959) Virol. 8:396) supplemented with 4.5 gm/l glucose, 20 mM glutamine, and 20% fetal caf serum.
  • An exemplary inbred mouse strain is the Balb/c.
  • antibodies produced in non-human subjects are used therapeutically in humans, they are recognized to varying degrees as foreign and an immune response may be generated in the patient.
  • One approach for minimizing or eliminating this problem, which is preferable to general immunosuppression, is to produce chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region.
  • Such antibodies are the equivalents of the monoclonal and polyclonal antibodies described above, but may be less immunogenic when administered to humans, and therefore more likely to be tolerated by the patient.
  • Chimeric mouse-human monoclonal antibodies can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the constant region of a murine (or other species) monoclonal antibody molecule is substituted with a gene encoding a human constant region, (see Robinson et al.. International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al. U.S. Patent No.
  • a chimeric antibody can be further "humanized” by replacing portions of the variable region not involved in antigen binding with equivalent portions from human variable regions.
  • General reviews of "humanized” chimeric antibodies are provided by Morrison, S. L. (1985) Science 229: 1202-1207 and by Oi et al. ( 1986) BioTechniques 4:214. These methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of an immunoglobulin variable region from at least one of a heavy or light chain.
  • Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from an anti-CTLA4 antibody producing hybridoma.
  • the cDNA encoding the chimeric antibody, or fragment thereof, can then be cloned into an appropriate expression vector.
  • Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (see U.S. Patent 5.225,539 to Winter; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239: 1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060).
  • a human mAb directed against a human protein can be generated.
  • Transgenic mice carrying human antibody repertoires have been created which can be immunized with human protein or peptide immunogen. Splenocytes from these immunized transgenic mice can then be used to create hybridomas that secrete human mAbs specifically reactive with the human protein (see, e.g.. Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741 ; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication 92/03917; Lonberg, N.
  • Monoclonal antibodies can also be produced by other methods well known to those skilled in the art of recombinant DNA technology.
  • An alternative method referred to as the "combinatorial antibody display” method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies (for descriptions of combinatorial antibody display see e.g., Sastry et al. (1989) PNAS 86:5728; Huse et al. (1989) Science 246:1275; and Orlandi et al. (1989) PNAS
  • immunoglobulin molecules by using a mixture of oligomer primers and PCR.
  • mixed oligonucleotide primers corresponding to the 5' leader (signal peptide) sequences and/or framework 1 (FR1) sequences, as well as primer to a conserved 3' constant region primer can be used fpr PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al. ( 1991 ) Biotechniques H 11 :152-156).
  • a similar strategy can also been used to amplify human heavy and light chain variable regions from human antibodies (Larrick et al. (1991) Methods: Companion to Methods in Enzymology 2:106-110).
  • RNA is isolated from activated B cells of, for example, peripheral blood cells, bone marrow, or spleen preparations, using standard protocols (e.g., U.S. Patent No. 4,683,202; Orlandi, et al. PNAS (1989) 86:3833-3837; Sastry et al., PNAS (1989) 86:5728-5732; and Huse et al. (1989) Science 246:1275-1281.) First-strand cDNA is synthesized using primers specific for the constant region of the heavy chain(s) and each of the k and ⁇ light chains, as well as primers for the signal sequence.
  • variable region PCR primers the variable regions of both heavy and light chains are amplified, each alone or in combination, and ligated into appropriate vectors for further manipulation in generating the display packages.
  • Oligonucleotide primers useful in amplification protocols may be unique or degenerate or incorporate inosine at degenerate positions. Restriction endonuclease recognition sequences may also be incorporated into the primers to allow for the cloning of the amplified fragment into a vector in a predetermined reading frame for expression.
  • the V-gene library cloned from the immunization-derived antibody repertoire can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library.
  • the display package comprises a system that allows the sampling of very large diverse antibody display libraries, rapid sorting after each affinity separation round, and easy isolation of the antibody gene from purified display packages.
  • kits for generating phage display libraries e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01 ; and the Stratagene SurfZ4P TM phage display kit. catalog no.
  • examples of methods and reagents particularly amenable for use in generating a variegated antibody display library can be found in, for example. Ladner et al. U.S. Patent No. 5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al.
  • the antibody library is screened with a protein, or peptide fragment thereof, to identify and isolate packages that express an antibody having specificity for the protein.
  • Nucleic acid encoding the selected antibody can be recovered from the display package (e.g., from the phage genome) and subcloned into other expression vectors by standard recombinant DNA techniques.
  • the V region domains of heavy and light chains are expressed on the same polypeptide, joined by a flexible linker to form a single-chain Fv fragment, and the scFV gene is subsequently cloned into the desired expression vector or phage genome.
  • an agent used to inhibit a T cell response is a soluble form of a costimulatory receptor on the surface of a T cell, or a a costimulatory molecule on the surface of a cell which presents antigen to the T cell.
  • This soluble protein is capable of inhibiting an interaction between the surface form of the molecule and its ligand(s) (and/or inhibiting an interaction between a related surface molecule having similar binding specificity and its ligand (s)).
  • soluble forms of CTLA4, B7-1 and or B7-2 can be used.
  • a preferred agent for use in the inhibiting donor T cell responses in bone marrow transplantation is a soluble form of a CTLA4 molecule (in particular, a CTLA4-immunoglobulin fusion protein) which binds to both B7-1 and B7-2, and can inhibit the interaction of B7-1 and B7-2 with CD28 and/or CTLA4.
  • a CTLA4 molecule in particular, a CTLA4-immunoglobulin fusion protein
  • Soluble forms of surface-bound proteins can be made using standard recombinant DNA and protein expression techniques known in the art.
  • Nucleic acid comprising a nucleotide sequence encoding the extracellular domain (or portion thereof) of a surface-bound protein of interest (i.e., lacking the nucleotide sequence of the transmembrane and cytoplasmic domains) can be isolated and cloned into a standard expression vector, either for expression in prokaryotic or eukaryotic cells.
  • the expression vector is introduced into an appropriate host cell (e.g., E.
  • yeast or mammalian cells e.g., COS, CHO or NSO cells, for eukaryotic expression
  • the protein is then purified by standard techniques from harvested host cells or, if the protein is secreted from the cells, from the media in which the cells are cultured.
  • the extracellular domain (or portion thereof) of a surface-bound protein can be expressed recombinantly as a non-fusion protein, or more preferably, is expressed as a fusion protein with a second protein or polypeptide.
  • fusion protein refers to a protein composed of a first polypeptide operatively linked to a second, heterologous, polypeptide.
  • a preferred type of fusion protein to be used as an agent in the methods of the invention is an immunoglobulin fusion protein (e.g., CTLA4Ig).
  • immunoglobulin fusion protein refers to a fusion protein in which the second, heterologous polypeptide is an immunglobulin constant region, or portion thereof.
  • Immunoglobulin fusion proteins have been described extensively in the art (see e.g., U.S. Patent No. 5,116,964 by Capon et al.; Capon, D.J. et al. (1989) Nature 337:525-531; and Aruffo, A. et al. (1990) Cell 61:1303-1313), and typically include at least a functionally active hinge region, CH 2 and CH 3 domains of a constant region of an immunoglobulin heavy chain (e.g., human C ⁇ 1, C ⁇ 4). Construction of a B7-1-Ig fusion protein and a CD28Ig fusion protein is described in detail in Linsley, P.S. et al. (1991) J. Exp. Med.
  • CTLA4Ig fusion protein Construction of a CTLA4Ig fusion protein is described in detail in Linsley, P.S. et al. (1991) J. Exp. Med. 174:561-569 and Gimmi, CD. et al. (1993) Proc. Natl. Acad. Sci. USA 90:6586.
  • Other Ig fusion proteins e.g., B7-2-Ig
  • B7-2-Ig can be similarly prepared.
  • a peptide, peptide mimetic, or other form of small molecule which inhibits an interaction between a receptor and a costimulatory molecule can be used to inhibit a costimulatory signal in a T cell.
  • a peptide, peptide mimetic, or other form of small molecule which inhibits adhesion or a T cell to a cell presenting antigen to the T cell, or inhibits an interaction between a T cell growth factor and its receptor on a T cell, can be used as a second agent in conjunction with a costimulation inhibitory agent to inhibit a T cell response.
  • an agent which acts intracellularly to interfere with the formation of an intracellular signal(s) associated with a particular signal transduction pathway can be used to inhibit a T cell response.
  • a costimulation inhibitory agent as described herein can be an agent that acts intracellularly to inhibit a CD28- or CTLA4-associated signal transduction pathway.
  • CD28 stimulation has been shown to result in protein tyrosine phosphorylation in T cells (see e.g., Vandenberghe. P. et al.
  • a tyrosine kinase inhibitor such as herbimycin A
  • a CD28-associated signal transduction pathway can be inhibited using an agent which stimulates protein tyrosine phosphatase activity in a T cell, thereby decreasing the net amount of protein tyrosine phosphorylation.
  • an antibody directed against the cellular tyrosine phosphatase CD45 can be used to stimulate tyrosine phosphatase activity in a T cell expressing CD45 on its surface.
  • Other intracellular signals reported to be associated with CD28 ligation include increased phospholipase C activity (see e.g., Nunes, J. et al. (1993) Biochem. J. 293:835-842) and increased intracellular calcium levels (see e.g. Ledbetter, J.A. et al. (1990) Blood 75:1531-1539). Accordingly, an agent which inhibits phospholipase C activity and/or inhibits increases in intracellular calcium levels can be used to inhibit the generation of a costimulatory signal in a T cell.
  • a preferred composition of the invention comprises a CTLA4Ig fusion protein, in an amount effective to inhibit a T cell response, and a pharmaceutically acceptable carrier.
  • the agents of the invention are administered to subjects in a biologically compatible form suitable for pharmaceutical administration in vivo to inhibit a T cell response.
  • biologically compatible form suitable for administration in vivo is meant a form of the protein to be administered in which any toxic effects are outweighed by the therapeutic effects of the ligand.
  • subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, monkeys, dogs, cats, mice, rats, and transgenic species thereof.
  • a therapeutically active amount of one or more of the agents described herein is defined as an amount effective, at dosages and for periods of time necessay to achieve the desired result.
  • a therapeutically active amount of a CTLA4Ig fusion protein may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the fusion protein to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be
  • the active agent e.g., antibody and/or fusion protein
  • the active agent may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration.
  • the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
  • To administer an agent by other than parenteral administration it may be necessary to coat the agent with, or co-administer the agent with, a material to prevent its inactivation.
  • An agent may be administered to an individual in an appropriate carrier or diluent, co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes.
  • diluents include saline and aqueous buffer solutions.
  • Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol.
  • Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984) J. Neuroimmunol 7:21). Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active agent in the required amount of an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., protein) plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the compound When the active compound is suitably protected, as described above, the compound may be orally administered, for example, with an inert diluent or an assimilable edible carrier.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
  • the methods of the invention can be used to inhibit T cell responses in vitro by contacting a T cell with a costimulation inhibitory agent as described herein. Accordingly, the term "contacting" as used herein is intended to include incubating (or culturing) a T cell with the agent.
  • the methods of the invention are useful in therapeutic situations where it is desirable to inhibit an unwanted T cell response, as described in further detail in the subsections to follow.
  • the methods of the invention induce antigenic nonresponsiveness in a T cell that persists after cessation of treatment (i.e., antigenic nonresponsiveness persists in vivo after contacting T cells in vitro with a costimulation inhibitory agent).
  • the methods of the invention are useful for inducing T cell anergy, thereby providing a means for long-term inhibition of T cell responses without the need for chronic generalized immunosuppression of a subject with its attendant deleterious side effects.
  • the methods of the invention are particularly useful for inhibiting graft versus host disease which results from allogeneic bone marrow transplantation. It has previously been observed that the presence of mature donor T cells within a bone marrow graft is beneficial both for successful engraftment and for a graft versus leukemia response. However, the presence of mature donor T cells in the graft induces GVHD. Responses of alloreactive donor T cells can be inhibited by contacting the T cells in vitro with a costimulation inhibitory agent (e.g., a costimulation blocking agent, such as a combination of an anti-B7-1 and an anti-B7-2 antibody, or CTLA4Ig).
  • a costimulation inhibitory agent e.g., a costimulation blocking agent, such as a combination of an anti-B7-1 and an anti-B7-2 antibody, or CTLA4Ig.
  • Such treatment allows mature T cells to be present within transplanted donor cells, thus avoiding GVHD and promoting bone marrow engraftment. Moreover, T cell unresponsiveness to alloantigens is induced, thereby providing long-term inhibition of T cell responses without the need for continuous treatment of the bone marrow recipient.
  • graft versus host disease in a bone marrow transplant recipient is inhibited by contacting a population of donor T cells in vitro (prior to transplantation) with 1) a second population of cells expressing recipient alloantigens (such as recipient cells or cells from another source which share recipient alloantigens, e.g., major or minor histocompatibility antigens) and 2) an agent which inhibits a costimulatory signal in a donor T cell.
  • recipient alloantigens such as recipient cells or cells from another source which share recipient alloantigens, e.g., major or minor histocompatibility antigens
  • the agent which inhibits a costimulatory signal is a CTLA4Ig fusion protein.
  • the agent is an anti-B7-1 or anti-B7-2 antibody (or fragment therof).
  • the agent is a combination of an anti-B7-1 antibody and an anti-B7-2 antibody.
  • the agent is a single antibody which binds both B7-1 and B7-2.
  • the second population of cells, which express recipient alloantigens, are typically treated such that they cannot proliferate and/or are not metabolically active, e.g., the cells are irradiated and/or treated with paraformaldehyde.
  • the population of donor cells contacted with the inhibitory agent(s) include mature donor T cells.
  • the population of donor cells used in the method can be, for example, the bone marrow cells themselves which are to be transplanted into the recipient which have not been T cell depleted.
  • the source of mature donor T cells can be donor peripheral blood cells, splenocytes or other suitable source of donor T cells.
  • the subsequent bone marrow graft includes a mixture of bone marrow cells and nonbone marrow cells (i.e., bone marrow cells together with mature donor T cells in which alloreactivity has been inhibited).
  • the donor cells are administered to the recipient (if the donor cells used in the in vitro culture do not include bone marrow cells, e.g., if peripheral blood cells or splenocytes are uses as the source of mature donor T cells. then T-cell depleted bone marrow cells are also administered to the recipient).
  • the recipient is further treated in vivo with the inhibitory agent(s). That is. a costimulation inhibitory agent can be administered to the recipient alone or with a another agent, such as an immunosupressive agent (e.g., cyclosporine A) or only the inhibitory agent(s).
  • a costimulation inhibitory agent can be administered to the recipient alone or with a another agent, such as an immunosupressive agent (e.g., cyclosporine A) or only the
  • immunosupressive agent can be administered in vivo.
  • the stimulator cells had been previously inactivated by treatment with mitomycin C or by irradiation before addition. All of these experiments were performed in the absence or presence of graded concentrations of CTLA4Ig for the entire incubation period.
  • the cultures were pulsed with [ 3 H]-thymidine overnight between days 2 and 3 of culture.
  • the cultures were pulsed with [ 3 H]-thymidine overnight between days 4 and 5 of culture.
  • the amount of radioactivity incorporated into the dividing responder T cells determined their level of proliferation. These time points were chosen because they had been previously shown to be at or near the proliferation maxima.
  • Figure 3 A shows the inhibition of donor marrow proliferation by amounts of
  • CTLA4Ig below 1 ⁇ g/ml.
  • the proliferative response to the human B7-1 transfected cells is completely inhibited by CTLA4Ig levels of between 2 and 5 ⁇ g/ml.
  • CTLA4Ig levels of 2 ⁇ g/ml and 1 ⁇ g/ml, respectively. Since the proliferation driven by the allogeneic PBL was almost completely inhibited by 1 ⁇ g/ml of CTLA4Ig and was completely inhibited by 2 ⁇ g/ml CTLA4Ig, a dosage of 10 ⁇ g/ml of CTLA4Ig was selected for use in all subsequent experiments.
  • the antibodies and CTLA4Ig were added at a concentration of 10 ⁇ g/ml.
  • Cyclosporin A was used at 10 -3 M. The cells were incubated for 6 days, following which viable cells were isolated and rechallenged with irradiated allogeneic cells from the original donor or from a third party donor. No blocking agents were added to this secondary MLR. Proliferation was examined daily for 7 days by [ 3 H]-thymidine incorporation assays.
  • B7-2 costimulation is achieved within 36 hours This example analyses the time of inhibition of costimulation required to obtain maximal hyporesponsiveness for different agents blocking costimulation.
  • Example 2 the same assay as that used in Example 2 was used.
  • Cells were cultured in a primary MLR with the addition of anti-B7-1, anti-B7-2, a combination of anti-B7-1 and anti-B7-2, or CTLA4Ig. After various times, viable cells were isolated, rechallenged with irradiated cells from the original donor with no blocking agent added and proliferation assessed daily for 7 days. Peak proliferation obtained on any day in the secondary MLR was assessed by [ 3 H]-thymidine incorporation.
  • Non-reactivity in a matched sibling MLR is a poor predictor of subsequent GVHD.
  • a high frequency of alloreactive donor pHTL is associated with subsequent development of acute GVHD (Theobald, M., et al.
  • Stimulator cells at 10 6 cells/well were irradiated (25 Gy) and mixed with 10 5 unirradiated responder cells from fully HLA matched siblings. After incubation of the cells for 36 hours in the presence of media alone or with anti-B7-1 mAb, anti-B7-2 mAb, anti-B7- 1 mAb and anti-B7-1 mAb, CTLA4Ig, or control immunoglobulin (CIg), the cells were irradiated (25Gy) and CTLL-2 cells were added and the culture was continued for a further 24 hours. Proliferation was assessed by tritiated thymidine incorporation for the last 16 hours or the assay. pHTL frequencies were calculated from the proportion of wells negative for IL- 2 production by limiting dilution analysis (Taswell C. (1981) J. Immunol. 126, 1614).
  • the pHTL frequency in fully HLA matched pairs ranged from 1.25 ⁇ 10 -4 to 8 ⁇ 10 -7 .
  • Culture with media during primary stimulation did no alter this frequency.
  • Complete blockade of B7 family mediated costimulation by either the addition of the combination of anti-B7-1 and anti-B7-2 or CTLA4-Ig during primary stimulation markedly reduced the pHTL frequency against donor on rechallenge.
  • the addition of anti-B7-1 mAb or control Ig had no effect whereas anti-B7-2 had very modest effect.
  • the pHTL frequencies achieved with complete B7 blockade were consistently ⁇ 1 ⁇ 10 5 that is below the level associated with development of GVHD.
  • T cells pHTL is reduced.
  • This reduction in the frequency of the pHTL in the donor marrow anergized by treatment with CTLA4Ig is important because it has been demonstrated that the development of GVHD after bone marrow transplantation is directly associated with the frequency of the population of T cells.
  • Donor pHTL frequencies were calculated using a limiting dilution assay (LDA) in which dilutions of donor cells were incubated with stimulator or third party cells in microtiter dishes. The supematants from these cultures were then tested for their ability to support the proliferation of an IL-2 dependent CTLL cell line. This assay is very sensitive and measures the production of IL-2 by the treated donor marrow cells in response to various stimulators. The proliferation of the CTLL cell line is dependent on IL-2.
  • LDA limiting dilution assay
  • FIG. 7 shows the pHTL frequency found in the donor marrow after anergization for 48 hours in the presence of 10 ⁇ g /ml of CTLA4Ig.
  • Each point in this figure represents the data obtained from a different donor marrow MHC mismatched allogeneic stimulator cell pair. Untreated cells incubated in media alone show a pHTL frequency of approximately 10 -2 when tested against the original stimulator cell population. This agrees with the pHTL frequency expected for a mismatched responder and stimulator pair.
  • donor marrow anergized by treatment with CTLA4Ig shows a dramatic reduction in the pHTL frequency when tested against the original stimulator cells (approximately 10 - 5 ). The reduction in pHTL frequency is approximately 1000 fold.
  • the specificity of the reduction in pHTL frequency towards the allogeneic stimulator cells is shown by measuring the pHTL frequency against third party PBLs which are MHC disparate with both the bone marrow and the original stimulator cells.
  • the frequency of pHTL directed against the third party cells is approximately 10 -2 .
  • the pHTL frequency determined for the response of anergized donor marrow against third party cells is comparable with that found for untreated marrow. This demonstrates that the anergization of the donor marrow by exposure to allogeneic stimulators in the presence of CTLA4Ig results in the generation of a hypo responsiveness to the tolerizing stimulator cells but has no effect on the responsiveness to other alloantigens.
  • pHTL frequency (10 - 2 ) was comparable to that for untreated cultures demonstrating that the dramatic reduction seen in pHTL frequency in cultures treated with CTLA4Ig was not due to the effect of the Ig sequences, nor was it due to a general immuosuppression as can be obtained with cyclosporine A.
  • the level of reduction in pHTL frequency after treatment with anti-B7-1 and anti-B7-2 antibodies or CTLA4Ig is consistent with a reduction in pHTL sufficient to reduce or eliminate GVHD. Furthermore, the combination of anti-B7-1 and anti-B7-2 antibodies was consistently more efficient than CTLA4 in blocking proliferation in a primary and a secondary MLR with fully HLA mismatched donor and recipient cells and in decreasing pHTL frequencies.
  • This experiment was conducted to determine the effect of treatment with CTLA4Ig on cell lineage precursor or stem cells present in the donor marrow population.
  • Colony forming assays and long term colony initiating cell (LTCIC) assays were performed on donor marrow before treatment, after incubation in media alone or in the presence of control Ig protein (10 ⁇ g/ml) or CTLA4Ig (10 ⁇ g/ml). Briefly, the marrow sample was washed extensively, the viable cell number determined, and the cells plated at 100,000 cells/ml in methylcellulose medium which contained growth factors appropriate for human cells. These assays were set up in triplicate for each patient's marrow sample.
  • BFU-E erythrocytic
  • CFU-GM myelomonocytic
  • the direct colony forming assay shows that there are similar numbers of BFU-E and CFU-GM precursors in all six patient samples tested regardless of whether the assays were performed on donor marrow before treatment or after culturing donor marrow with irradiated stimulators for 48 hours in the presence of medium alone or in medium containing control Ig or CTLA4Ig. Similar results are seen in the three patient samples tested by the LTCIC methodology. This method is a more sensitive measurement of damage to stem cells than is the direct colony forming assay. All three patient samples tested have similar numbers of BFU-E and CFU-GM colony forming units after treatment as did the fresh donor marrow samples.
  • the experimental data presented in Table I shows that the culturing protocol developed for the anergization of donor bone marrow to sensitizing alloantigens by the treatment with CTLA4Ig had no detrimental effect on the donor bone marrow.
  • the donor bone marrow had the same number of cells before and after treatment.
  • the donor bone marrow retained a full complement of lineage specific blood cell precursors as demonstrated in both direct colony forming assays and in the more sensitive LTCIC assays.
  • the donor bone marrow exhibited a dramatic and specific decrease in the responsiveness to the sensitizing alloantigens while it retained a full ability to respond to third party cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés permettant d'inhiber in vitro des réactions des cellules T spécifiques d'un antigène, au moyen d'un agent qui inhibe un signal costimulateur dans les cellules T, tel qu'une protéine de fusion CTLA4Ig ou un anticorps anti-B7-1 ou anti-B7-2. Les procédés selon l'invention servent particulièrement à inhiber la réaction du greffon contre l'hôte résultant d'une greffe de moelle osseuse allogénique.
PCT/US1995/014774 1994-11-10 1995-11-09 Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse WO1996014865A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41583/96A AU4158396A (en) 1994-11-10 1995-11-09 Methods for inhibiting graft versus host disease in bone marrow transplantation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33796094A 1994-11-10 1994-11-10
US08/337,960 1994-11-10

Publications (1)

Publication Number Publication Date
WO1996014865A1 true WO1996014865A1 (fr) 1996-05-23

Family

ID=23322778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014774 WO1996014865A1 (fr) 1994-11-10 1995-11-09 Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse

Country Status (2)

Country Link
AU (1) AU4158396A (fr)
WO (1) WO1996014865A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030232A1 (fr) * 1997-01-10 1998-07-16 The John P. Robarts Research Institute Procedes et compositions de prevention de maladies auto-immunes
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5869050A (en) * 1992-07-09 1999-02-09 Chiron Corporation Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
WO1998058965A3 (fr) * 1997-06-20 1999-05-14 Innogenetics Nv Molecules de liaison avec b7 destinees au traitement d'affections immunitaires
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2000047625A3 (fr) * 1999-02-12 2001-08-02 Genetics Inst Immunoglobuline humanisee reagissant avec des molecules b7 et methodes de traitement avec celles-ci
DE10131971A1 (de) * 2001-07-02 2003-01-30 Cytonet Gmbh & Co Kg Hämatopoetisches Stammzell-Präparat und Verfahren zu dessen Herstellung
US6827934B1 (en) 1999-02-12 2004-12-07 Genetics Institute, Llc Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith
US7105166B1 (en) 1991-06-27 2006-09-12 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US7439230B2 (en) 2000-05-26 2008-10-21 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US7455835B2 (en) 2000-07-03 2008-11-25 Bristol-Myers Squibb Company Methods for treating immune system diseases using a soluble CTLA4 molecule
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US8148332B2 (en) 2000-07-03 2012-04-03 Bristol-Myers Squibb Company Method for treating a rheumatic disease using a soluble TLA4 molecule
US9062111B2 (en) 2005-12-07 2015-06-23 Medarex, L.L.C. CTLA-4 antibody dosage escalation regimens
WO2020172391A1 (fr) * 2019-02-22 2020-08-27 The Children's Medical Center Méthodes et compositions se rapportant au traitement de la gvhd

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003408A1 (fr) * 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: contre-recepteur de ctla4/cd28
WO1995034320A2 (fr) * 1994-06-07 1995-12-21 Regents Of The University Of Minnesota Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003408A1 (fr) * 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: contre-recepteur de ctla4/cd28
WO1995034320A2 (fr) * 1994-06-07 1995-12-21 Regents Of The University Of Minnesota Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. R. BLAZAR ET AL.: "In vivo infusion of soluble CTLA4-Ig reduces lethal graft-versus-host disease (GVHD) induced across the major histocompatibility complex (MHC) barrier in mice", BLOOD, vol. 82, no. 10 Suppl. 1, pages 456A *
PAUL G. SCHLEGEL ET AL.: "Inhibition of T Cell Costimulation by VCAM-1 Prevents Murine Graft-Versus-Host Disease Across Minor Histocompatibility Barriers", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 8, pages 3856 - 3865 *
PETER S. LINSLEY ET AL.: "Immunosuppression and the CD28 receptor", PERSPECTIVES IN DRUG AND DISCOVERY DESIGN, vol. 2, no. 1, pages 221 - 231 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105166B1 (en) 1991-06-27 2006-09-12 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US5869050A (en) * 1992-07-09 1999-02-09 Chiron Corporation Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7229628B1 (en) 1995-07-25 2007-06-12 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6841152B1 (en) 1997-01-10 2005-01-11 The Wellesley Hosp. Foundation Methods for protecting against autoimmune diabetes
WO1998030232A1 (fr) * 1997-01-10 1998-07-16 The John P. Robarts Research Institute Procedes et compositions de prevention de maladies auto-immunes
WO1998058965A3 (fr) * 1997-06-20 1999-05-14 Innogenetics Nv Molecules de liaison avec b7 destinees au traitement d'affections immunitaires
US7531175B2 (en) 1999-02-12 2009-05-12 Genetics Institute Llc Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
WO2000047625A3 (fr) * 1999-02-12 2001-08-02 Genetics Inst Immunoglobuline humanisee reagissant avec des molecules b7 et methodes de traitement avec celles-ci
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6984383B1 (en) 1999-02-12 2006-01-10 Genetics Institute, Llc Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins
US6827934B1 (en) 1999-02-12 2004-12-07 Genetics Institute, Llc Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith
US6913747B1 (en) 1999-02-12 2005-07-05 Genetics Institute, Llc Humanized immunoglobulin reactive with B7 therewith
US7666421B2 (en) 1999-02-12 2010-02-23 Genetics Institute, Llc Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US8785398B2 (en) 2000-05-26 2014-07-22 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US9758565B2 (en) 2000-05-26 2017-09-12 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US7439230B2 (en) 2000-05-26 2008-10-21 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US10370428B2 (en) 2000-05-26 2019-08-06 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US7700556B2 (en) 2000-05-26 2010-04-20 Bristol-Myers Squibb Company Methods of treatment using CTLA4 mutant molecules
US9296808B2 (en) 2000-07-03 2016-03-29 Bristol-Myers Squibb Company Methods for treating scleroderma by administering a soluble CTLA4 molecule
US7455835B2 (en) 2000-07-03 2008-11-25 Bristol-Myers Squibb Company Methods for treating immune system diseases using a soluble CTLA4 molecule
US8227420B2 (en) 2000-07-03 2012-07-24 Bristol-Myers Squibb Company Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US8497247B2 (en) 2000-07-03 2013-07-30 Bristol-Myers Squibb Company Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule
US8703718B2 (en) 2000-07-03 2014-04-22 Bristol-Myers Squibb Company Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule
US8722632B2 (en) 2000-07-03 2014-05-13 Bristol-Myers Squibb Company Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule
US10052360B2 (en) 2000-07-03 2018-08-21 Bristol-Myers Squibb Company Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule
US8148332B2 (en) 2000-07-03 2012-04-03 Bristol-Myers Squibb Company Method for treating a rheumatic disease using a soluble TLA4 molecule
US7829534B2 (en) 2001-05-23 2010-11-09 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
DE10131971A1 (de) * 2001-07-02 2003-01-30 Cytonet Gmbh & Co Kg Hämatopoetisches Stammzell-Präparat und Verfahren zu dessen Herstellung
US9573999B2 (en) 2005-12-07 2017-02-21 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
US9062111B2 (en) 2005-12-07 2015-06-23 Medarex, L.L.C. CTLA-4 antibody dosage escalation regimens
WO2020172391A1 (fr) * 2019-02-22 2020-08-27 The Children's Medical Center Méthodes et compositions se rapportant au traitement de la gvhd

Also Published As

Publication number Publication date
AU4158396A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
US7592007B2 (en) Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies
AU2701895A (en) Methods for inhibiting antigen specific t cell responses
DE69519513T2 (de) Verfahren zur modulation von "t-zell-anergy"
FI118792B (fi) Käyttöjä T-solutoleranssin indusoinniksi kudos- tai elinsiirrännäiselle
CN115052902B (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
WO1996014865A1 (fr) Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
TW202503052A (zh) 嵌合受體和使用彼之方法
US6576236B1 (en) Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20060233795A1 (en) Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
US20020127201A1 (en) Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
Alfar et al. Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
AU748561B2 (en) Methods for inhibiting antigen specific T cell responses
Katsumata et al. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance–an experimental study
WO1997017360A2 (fr) Procedes de modulation des reponses des lymphocytes t par manipulation d'une chaine gamma commune de recepteurs de cytokine
AU2006202939B2 (en) Methods of modulating T cell unresponsiveness
AU784510B2 (en) Methods for modulating T cell unresponsiveness
Brouard Anti-CD28 Antibody-Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR-Class II-B7+ Regulatory Cells
WO2001000679A2 (fr) Procedes permettant d'induire une tolerance des cellules t a une greffe de tissu ou d'organe
AU3794299A (en) Methods for modulating T cell unresponsiveness
HK1016019B (en) Methods for modulating t cell anergy
HK1014720B (en) Ligands for induction of antigen specific apoptosis in t cells
AU4112399A (en) Ligands for induction of antigen specific apoptosis in T cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA